procarbazine + thiotepa + vincristine

This is a chemotherapy combination regimen used primarily for treating recurrent malignant supratentorial gliomas. The combination consists of three distinct drugs that work together to target cancer cells. The regimen typically involves procarbazine given at a dose of 100 mg/m² orally from day 1, combined with thiotepa and vincristine[1]. This combination is sometimes referred to as PTV in medical literature. ## Administration and Dosing Each component of this combination has a specific administration method: - **Procarbazine**: Taken orally as capsules with a full glass of water - **Thiotepa**: Typically administered intravenously - **Vincristine**: Given intravenously, often through a central line, PICC line, or portacath[3] ## Mechanism of Action These chemotherapy drugs work by destroying rapidly dividing cells, particularly cancer cells[3]. Each drug in the combination has its own mechanism: - **Procarbazine**: An alkylating agent that damages DNA in cancer cells - **Thiotepa**: Another alkylating agent that cross-links DNA strands - **Vincristine**: A vinca alkaloid that disrupts microtubule formation, preventing cell division ## Clinical Applications This combination has been used in several clinical contexts: 1. Treatment of recurrent malignant supratentorial gliomas[1] 2. As part of treatment regimens for primary central nervous system lymphoma (PCNSL)[2][5] Similar combinations like R-MPV (rituximab, methotrexate, procarbazine, and vincristine) have been used for newly diagnosed PCNSL, sometimes followed by high-dose chemotherapy with thiotepa-based regimens[2][5]. ## Side Effects The combination can cause various side effects, including: - Allergic reactions (rash, shortness of breath, facial swelling) - Blood pressure changes - Potential tissue damage if vincristine leaks outside the vein during administration (extravasation) - Various hematological toxicities Patients receiving this combination require careful monitoring and supportive care to manage these potential adverse effects[3].